IN2014DN03325A - - Google Patents

Info

Publication number
IN2014DN03325A
IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
Authority
IN
India
Prior art keywords
compound
directed
composition
sulphur
selene
Prior art date
Application number
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Johannes Maria Melief
Selina Khan
Dmitri Viktorovitsj Filippov
Marel Gijsbert Arie Van Der
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of IN2014DN03325A publication Critical patent/IN2014DN03325A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IN3325DEN2014 2011-10-05 2012-10-04 IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (1)

Publication Number Publication Date
IN2014DN03325A true IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-26

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3325DEN2014 IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-10-05 2012-10-04

Country Status (16)

Country Link
US (2) US9314521B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2763697B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6099210B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102053699B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104244976B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012319265B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014008214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2886631C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA030741B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2952644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL231951B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX356028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL2007536C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201401291XA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013051936A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3148566B1 (en) 2014-06-02 2024-04-03 ISA Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
WO2017145097A2 (en) 2016-02-26 2017-08-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3552623A1 (en) 2016-06-20 2019-10-16 ISA Pharmaceuticals B.V Formulation of a peptide vaccine
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
CN110650750A (zh) 2017-04-04 2020-01-03 阿维迪科技公司 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
AU2020397499A1 (en) 2019-12-07 2022-06-16 Erasmus University Medical Center Rotterdam Treatment of diseases related to hepatitis B virus
EP4100051A2 (en) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
EP4138876A1 (en) 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
CN117730247A (zh) 2021-07-12 2024-03-19 Isa制药有限公司 复杂混合物中改善的物质定量
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
AU2023361181A1 (en) 2022-10-13 2025-05-22 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
BR0012069A (pt) 1999-06-30 2002-08-27 Corixa Corp Composições e métodos para a terapia e diagnóstico de câncer pulmonar
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
JP5649952B2 (ja) 2007-03-26 2015-01-07 アカデミシュ・ジーケンフイス・レイデン・エイチ.オー.デー.エヌ.・エルユーエムシーAcademisch Ziekenhuis Leiden h.o.d.n. LUMC Prame由来ペプチド及びこれらを含んでいる免疫原性組成物
CA2689536A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
CA3167595A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний

Also Published As

Publication number Publication date
AU2012319265B2 (en) 2016-10-13
SG11201401291XA (en) 2014-05-29
WO2013051936A9 (en) 2013-09-12
WO2013051936A1 (en) 2013-04-11
EP2763697A1 (en) 2014-08-13
ES2952644T3 (es) 2023-11-02
EP2763697B9 (en) 2023-10-04
NZ623869A (en) 2015-11-27
MX2014004114A (es) 2014-10-17
AU2012319265A1 (en) 2014-05-22
MX356028B (es) 2018-05-09
JP6099210B2 (ja) 2017-03-22
EA201490709A1 (ru) 2014-09-30
NL2007536C2 (en) 2013-04-08
EP2763697B1 (en) 2023-06-07
JP2014530808A (ja) 2014-11-20
BR112014008214A2 (pt) 2017-06-13
BR112014008214B1 (pt) 2022-07-05
US20150104473A1 (en) 2015-04-16
CN104244976B (zh) 2017-05-31
KR20140093673A (ko) 2014-07-28
US9770506B2 (en) 2017-09-26
CA2886631A1 (en) 2013-04-11
US20160250325A1 (en) 2016-09-01
IL231951B (en) 2019-08-29
EA030741B1 (ru) 2018-09-28
CN104244976A (zh) 2014-12-24
KR102053699B1 (ko) 2019-12-09
CA2886631C (en) 2019-06-11
EP2763697C0 (en) 2023-06-07
EP2763697B8 (en) 2023-07-12
IL231951A0 (en) 2014-05-28
US9314521B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2016077464A8 (en) Amino acid derivatives and their uses
MY200083A (en) Cyclic dinucleotide compounds
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
PH12012501918A1 (en) Process for preparation of dopo-derived compounds and compositions thereof
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
MY150596A (en) Hsp90 inhibitors
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
JO2910B1 (en) Organic compounds
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
MX2011007952A (es) Tricianoboratos novedosos.
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
MX352607B (es) Proceso para la preparacion de benzoxaboroles.
BR112013001132A2 (pt) processo para preparação de compostos antivirais
PH12013500694A1 (en) Process for manufacturing dihydropteridinones and intermediates thereof
MY167638A (en) Treatment composition for textile goods
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
NZ704155A (en) Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX2013003387A (es) Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional.
UY32975A (es) Derivados de aminopiridina
BR112013024361A2 (pt) novos compostos de azaspirodecanona como inibidores de hsl